Which scan best spots remaining tumor after chemo?
NCT ID NCT07441330
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study looked at 42 women with advanced breast cancer who had chemotherapy before surgery. It compared three imaging tests—PET-CT, ultrasound, and MRI—to see which one best measures leftover tumor. The goal was to help doctors choose the right surgery, but the study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
42 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female patient * Patient aged 18 years or older at the time of inclusion in the study. * Patient with a diagnosis of advanced local invasive breast cancer, according to the TNM classification * Patient scheduled for neoadjuvant chemotherapy after multidisciplinary tumor board meeting, and without contraindications after pre-treatment assessment * Patient who has had a pre-cancer ultrasound, MRI, and/or PET scan * Patient capable and willing to follow the protocol procedures according to the investigator * Patient affiliated with or covered by a social security plan * Patient who has given her free, informed, and explicit written consent Exclusion Criteria: * Patient with metastatic cancer * Patient with another untreated associated cancer * Patient already treated with CNA * Patient who has been treated for cancer within the 5 years preceding their inclusion in the study * Patient whose physical and/or psychological health is severely impaired, which, according to the investigator, may affect the participant's compliance with the study. * Patient participating in another research study * Patient on exclusion from another ongoing research study at the time of inclusion. Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision. * Pregnant, breastfeeding, or parturient woman. * Patient hospitalized without consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Privé Paul d'Egine
Champigny-sur-Marne, 94500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?